TC 2559

Drug Profile

TC 2559

Latest Information Update: 22 Aug 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Targacept
  • Developer sanofi-aventis; Targacept
  • Class Neuroprotectants; Pyridines
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 29 Sep 2004 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
  • 15 Oct 2003 A preclinical study has been added to the Alzheimer's disease and pharmacodynamics section
  • 16 Apr 2002 The agreement between Aventis and Targacept has been extended
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top